Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • A ‘milestone’ moment: why economists think the global cycle of rate rises is over
    • OSCE in crisis as Russian veto threatens security body
    • Olaf Scholz accuses Poland of ‘waving through’ refugees as visa scandal deepens
    • Singapore banks tighten scrutiny of clients after money-laundering scandal
    • ‘What adjectives describe Xi Jinping?’ China’s new English textbook asks
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Private equity firms pivot away from traditional buyouts
      • German fintech Solaris struggles to raise funds to execute major contract
      • Sale of THG boss’s business park falls through
      • EDF chief and French government clash over strategy
      • UK press slams axing of Facebook News as ‘urgent threat to democracy’
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Hedge funds rush to unwind bets against gilts
      • Jeremy Hunt plans Isa overhaul to boost share ownership
      • Singapore banks tighten scrutiny of clients after money-laundering scandal
      • German fintech Solaris struggles to raise funds to execute major contract
      • The risks of money-market funds need careful watching
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A multi-speed Europe holds the key to EU enlargement
      • America’s mini economic miracle may be fleeting
      • Populism could derail the green transition
      • Russell Brand learnt his tricks in television studios
      • How to save your state pension
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • What Burberry taught me about the marketed mind
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • ‘There is no work to balance’: how shrinking budgets, Covid and AI shook up life in consulting
      • FT Business Books — what to read this month
      • Can I start a business when I have MS?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Raffles London and the new era of super-luxe hospitality
      • Anna Wintour: ‘I just have to make sure things are being done right’
      • Who’d invite the boss to dinner?
      • The best museum gift shops in the world
      • 17 chefs share the side dishes they can’t do without
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Wellcome Trust

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 28 June, 2023
      Disease control and prevention
      Gates Foundation and Wellcome fund $550mn trial of first new TB vaccine for 100 years

      Large-scale study will test GSK’s jab in 26,000 people in Africa and south-east Asia

      A mobile TB clinic in Kondoa District, Tanzania
    • Sunday, 28 May, 2023
      InterviewLeadership
      Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’

      The former head of the US defence department’s research agency was behind big bets on mRNA technology

      Regina Dugan
    • Friday, 5 May, 2023
      Wellcome Trust to triple size of Cambridge genome campus

      Biggest biomedical charity makes first investment in science infrastructure from its endowment

    • Tuesday, 10 January, 2023
      Wellcome vows to boost spending even if endowment has to be tapped

      Charity’s chair Julia Gillard commits to £16bn investment in science and health over next decade

      Julia Gillard
    • Wednesday, 10 August, 2022
      Racial equality
      Wellcome vows action to counter its ‘institutional racism’

      Medical charity will introduce funding stream aimed at black and minority researchers

      Jeremy Farrar
    • Tuesday, 18 January, 2022
      Bill Gates
      Bill Gates warns of pandemics potentially far worse than Covid

      Philanthropist calls on governments to contribute billions to tackle future pathogens and increase vaccine supplies

      Bill Gates
    • Tuesday, 11 January, 2022
      Medical science
      Wellcome Trust in £16bn spending pledge as world prepares for endemic Covid

      Top UK medical charity to focus on next generation vaccines as it warns of complacency over future variants

      Sir Jeremy Farrar, of the Wellcome Trust
    • Tuesday, 2 November, 2021
      Coronavirus
      Wellcome director resigns as UK government science adviser

      Jeremy Farrar calls Covid-19 picture ‘concerning’ but insists he is not leaving Sage as a protest

      Sir Jeremy Farrar, director, at the Wellcome Trust
    • Tuesday, 15 December, 2020
      Medical science
      Wellcome Trust hails ‘spectacular year’ for science

      Medical charity’s endowment boosted investments in research, much of it tied to pandemic

    • Friday, 6 November, 2020
      UK property
      Wellcome Trust to buy developer Urban&Civic for £506m

      Medical charity commits to long-term investment in regeneration-focused housebuilding

      A new housing development
    • Monday, 19 October, 2020
      Disease control and prevention
      How to spread the word about antibiotic resistance

      The FT is working with the Wellcome Trust to raise awareness of a growing threat

      A Petri dish of drug-resistant bacteria
    • Thursday, 20 August, 2020
      Coronavirus: free to read
      Why is the ‘anti-vaxxer’ movement growing during a pandemic?

      US concerns that Trump will rush to approve a vaccine before election is playing into wider safety fears

    • Thursday, 25 June, 2020
      News in-depthCoronavirus treatment20 min
      Coronavirus: the global race for a vaccine | FT Interview

      The Wellcome Trust's Jeremy Farrar on the prospects for a Covid-19 vaccine

    • Thursday, 14 May, 2020
      Wellcome goes global and appoints Julia Gillard as next chair

      Former Australian prime minister will be first non-Briton to head UK’s biggest charity

    • Tuesday, 7 April, 2020
      Impact investing
      Wellcome seeks $8bn from business to fight coronavirus

      Research group launches ‘Covid-zero’ to fund hunt for vaccines, treatments and testing

    • Monday, 30 March, 2020
      Coronavirus
      Gates Foundation and Wellcome Trust to fund Covid-19 drug trials 

      Accelerator fund will test whether existing drugs such as chloroquine can treat coronavirus

      Two of the trials will look at hydroxychloroquine (above) and chloroquine, which have shown promise in early studies on Covid-19 patients
    • Tuesday, 10 March, 2020
      Coronavirus
      Gates Foundation and Wellcome set up $125m coronavirus drug fund

      Research foundations join forces with Mastercard-backed charity to develop treatments

      MILAN, ITALY - MARCH 05: A lab worker tries to isolate the presence of Coronavirus during a swab test process in the Molecular biology laboratory of the Ospedale Niguarda, on March 05, 2020 in Milan, Italy.Over 3,089 people have been infected by the novel Coronavirus in Italy. Among these 107 people have died, (mainly because of a previous and serious clinical conditions compromised by the virus) 2,706 people have currently tested positive and 276 people have recovered, making Italy the hub of the epidemic in the west and pushing the Italian Government to issue extreme safety measures. (Photo by Emanuele Cremaschi/Getty Images)
    • Thursday, 23 January, 2020
      Miranda Wolpert
      Stop throwing money at mindfulness apps, puppies and yoga

      Mental wellbeing is a critical business issue and we should treat it as one

      Cute white poodle dog in the office under the table
    • Wednesday, 15 January, 2020
      Science
      Lab workers complain of long hours, bullying and stress

      Wellcome study reveals ‘shocking portrait of research environment’

      Health care researchers working in life science laboratory. Young female research scientist and senior male supervisor preparing and analyzing microscope slides in research lab.
    • Sunday, 5 May, 2019
      Pilita Clark
      The dream of a four-day week needs a lot more work

      A big employer has cancelled plans to pilot shorter hours, citing business disruption

      HA45R9 The interior of the Wellcome Library, London, England showcasing it's modern design.
    • Sunday, 21 April, 2019
      Pharmaceuticals sector
      We ignore the disaster in the antibiotics market at our peril

      There is no viable path for new drugs, however valuable they are to society

      A technician uses a multichannel pipette to transfer samples of bacteria into a tray of test tubes at a Bugworks Research India Ltd. laboratory in Bengaluru, India, on Thursday, May 31, 2018. The rapid spread of resistant bacteria has made India the epicenter of a war to prevent a post-antibiotic world, where people would once again die in their thousands of commonplace infections. Faced with this, the Indian government has begun to act, providing early research funding to startups like Bugworks and providing advice and support. Photographer: Samyukta Lakshmi/Bloomberg
    • Wednesday, 27 March, 2019
      Drugs research
      Industry must turn words into action on superbugs, says Jim O’Neill

      Biotech companies need big pharma to bring innovative antibiotics to market

      Christian LaVallee prepares solutions for polymerase chain reaction (PCR) tests at the Health Protection Agency in north London March 9, 2011. For decades scientists have managed to develop new medicines to stay at least one step ahead of the ever-mutating enemy, bacteria. Now, though, we may be running out of road. Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, alone is estimated to kill around 19,000 people every year in the United States -- far more than HIV and AIDS -- and a similar number in Europe, and other drug-resistant superbugs are spreading. Picture taken March 9, 2011. To match Special Report ANTIBIOTICS/ REUTERS/Suzanne Plunkett (BRITAIN - Tags: HEALTH SCI TECH) - GM1E73V1BEN01
    • Friday, 8 March, 2019
      Drugs research
      King’s and Wellcome sign US deal to develop painkillers

      Merck collaboration for new generation of pills could be worth as much as $340m

      Project leader Peter McNaughton of King’s Institute of Psychiatry. The deal is believed to be the most valuable achieved by a UK university for a specific drug development programme
    • Sunday, 9 September, 2018
      The FT ViewArtificial intelligence
      Artificial intelligence must avoid a backlash

      Governments and scientists need to co-operate to educate the public

      This photo taken on July 30, 2018 shows children playing with a Keeko robot after a class at the Yiswind Institute of Multicultural Education in Beijing. - In China, robots are being developed to deliver groceries, provide companionship to the elderly, dispense legal advice and now, as Keeko's creators hope, join the ranks of educators. (Photo by GREG BAKER / AFP) / TO GO WITH China-science-education-robot, FEATURE by Elizabeth LAW and Danni ZHUGREG BAKER/AFP/Getty Images
    • Friday, 17 August, 2018
      Pharmaceuticals sector
      Wellcome sanctions top cancer scientist over bullying allegations

      Charity will terminate £3.5m worth of grants to Nazneen Rahman

      Professor Nazneen Rahman Geneticist and doctor specialising in cancer gene discovery
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In